title: Multicenter comparison of serologic assays and estimation of human herpesvirus 8 seroprevalence among US blood donors.
abstract: BACKGROUND
  As part of assessing the possibility of transfusion transmission of human herpesvirus 8 (HHV-8 or Kaposi's sarcoma-associated herpesvirus), HHV-8 seroprevalence was estimated among US blood donors, the performance of HHV-8 serologic tests was compared, and the presence of HHV-8 DNA was tested for in donated blood.
  
  
  METHODS
  Replicate panels of 1040 plasma specimens prepared from 1000 US blood donors (collected in 1994 and 1995) and 21 Kaposi's sarcoma patients were tested for antibodies to HHV-8 in six laboratories. HHV-8 PCR was performed on blood samples from 138 donors, including all 33 who tested seropositive in at least two laboratories and 22 who tested positive in at least one.
  
  
  RESULTS
  The estimated HHV-8 seroprevalence among US blood donors was 3.5 percent (95% CI, 1.2%-9.8%) by a conditional dependence latent-class model, 3.0 percent (95% CI, 2.0%-4.6%) by a conditional independence latent-class model, and 3.3 percent (95% CI, 2.3%-4.6%) by use of a consensus-derived gold standard (specimens positive in two or more laboratories); the conditional dependence model best fit the data. In this model, laboratory specificities ranged from 96.6 to 100 percent. Sensitivities ranged widely, but with overlapping 95 percent CIs. HHV-8 DNA was detected in blood from none of 138 donors evaluated.
  
  
  CONCLUSIONS
  Medical and behavioral screening does not eliminate HHV-8-seropositive persons from the US blood donor pool, but no viral DNA was found in donor blood. Further studies of much larger numbers of seropositive individuals will be required to more completely assess the rate of viremia and possibility of HHV-8 transfusion transmission. Current data do not indicate a need to screen US blood donors for HHV-8.
authors.affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA. pelletp@ccf.org
authors.forename: P E
authors.initials: PE
authors.lastname: Pellett
authors.forename: D J
authors.initials: DJ
authors.lastname: Wright
authors.forename: E A
authors.initials: EA
authors.lastname: Engels
authors.forename: D V
authors.initials: DV
authors.lastname: Ablashi
authors.forename: S C
authors.initials: SC
authors.lastname: Dollard
authors.forename: B
authors.initials: B
authors.lastname: Forghani
authors.forename: S A
authors.initials: SA
authors.lastname: Glynn
authors.forename: J J
authors.initials: JJ
authors.lastname: Goedert
authors.forename: F J
authors.initials: FJ
authors.lastname: Jenkins
authors.forename: T-H
authors.initials: TH
authors.lastname: Lee
authors.forename: F
authors.initials: F
authors.lastname: Neipel
authors.forename: D S
authors.initials: DS
authors.lastname: Todd
authors.forename: D
authors.initials: D
authors.lastname: Whitby
authors.forename: G J
authors.initials: GJ
authors.lastname: Nemo
authors.forename: M P
authors.initials: MP
authors.lastname: Busch
mesh_terms: D000914:Antibodies, Viral / Q000097:blood; D001771:Blood Banks / Q000592:standards; D001782:Blood Donors / Q000706:statistics & numerical data*; D006566:Herpesviridae Infections / Q000097:blood* / Q000453:epidemiology* / Q000635:transmission; D019288:Herpesvirus 8, Human / Q000276:immunology / Q000302:isolation & purification*; D006801:Humans; D012015:Reference Standards; D012680:Sensitivity and Specificity; D016036:Seroepidemiologic Studies; D014481:United States / Q000453:epidemiology
chemical_list: D000914:Antibodies, Viral